AstraZeneca signs AI research deal with China's CSPC
Summary
AstraZeneca has signed a research deal worth up to $5.22 billion with China's CSPC to collaborate on using artificial intelligence for drug discovery and development. This partnership highlights the growing role of AI in accelerating pharmaceutical innovation and underscores increased international cooperation in AI-driven healthcare solutions.